David I. Quinn

1997–2025 年に発表

131
論文数
22,063
被引用数
75
h 指数
128
i10 指数

被引用数

David I. Quinn の年別被引用数1997 年: 被引用 2 件1999 年: 被引用 3 件2000 年: 被引用 5 件2001 年: 被引用 19 件2002 年: 被引用 40 件2003 年: 被引用 58 件2004 年: 被引用 68 件2005 年: 被引用 75 件2006 年: 被引用 83 件2007 年: 被引用 71 件2008 年: 被引用 79 件2009 年: 被引用 60 件2010 年: 被引用 78 件2011 年: 被引用 76 件2012 年: 被引用 94 件2013 年: 被引用 94 件2014 年: 被引用 102 件2015 年: 被引用 113 件2016 年: 被引用 109 件2017 年: 被引用 179 件2018 年: 被引用 274 件2019 年: 被引用 863 件2020 年: 被引用 1,109 件2021 年: 被引用 1,081 件2022 年: 被引用 829 件2023 年: 被引用 645 件2024 年: 被引用 1,078 件2025 年: 被引用 421 件2026 年: 被引用 6 件1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,019 件、この内訳の 25.4%中国: 引用元論文 1,221 件、この内訳の 10.3%イタリア: 引用元論文 755 件、この内訳の 6.3%イギリス: 引用元論文 684 件、この内訳の 5.8%ドイツ: 引用元論文 656 件、この内訳の 5.5%フランス: 引用元論文 558 件、この内訳の 4.7%カナダ: 引用元論文 451 件、この内訳の 3.8%日本: 引用元論文 441 件、この内訳の 3.7%スペイン: 引用元論文 434 件、この内訳の 3.6%オーストラリア: 引用元論文 368 件、この内訳の 3.1%オランダ: 引用元論文 354 件、この内訳の 3%スイス: 引用元論文 274 件、この内訳の 2.3%
0%25.4%その他 22.5%

分野

  • Medicine75.9%
  • Biochemistry, Genetics and Molecular Biology15.5%
  • Immunology and Microbiology2.6%
  • Neuroscience1.7%
  • Engineering0.7%
  • Computer Science0.6%
  • その他3%

トピック

  • Cancer Immunotherapy and Biomarkers9.1%
  • Bladder and Urothelial Cancer Treatments6.6%
  • Prostate Cancer Treatment and Research4.5%
  • Renal cell carcinoma treatment2.9%
  • Prostate Cancer Diagnosis and Treatment2.6%
  • Urinary and Genital Oncology Studies2.6%
  • その他71.7%

共著者

全論文

検索で開く
  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 3,390

  2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 被引用: 2,211

  3. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746

  4. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 327

  5. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 被引用: 788

  6. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 267

  7. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz ほか 133 名 - The Lancet Oncology 2022 被引用: 278

  8. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 488

  9. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 463

  10. Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression

    著者: , , , , , , , , , , , - Cell stem cell 2014 被引用: 488

  11. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

    著者: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 被引用: 501

  12. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 85

  13. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 568

  14. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 94

  15. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xueying Chen, Kun Yu, Dale Porter, Diana Graus Porta, Dean F. Bajorin - Cancer Discovery 2018 被引用: 257

  16. Radium-223 mechanism of action: implications for use in treatment combinations

    著者: , , , , , , , - Nature Reviews Urology 2019 被引用: 121

  17. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

    著者: , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 被引用: 262

  18. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 37

  19. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

    著者: , , , , , , , , , , , , , , , , , - Annals of Oncology 2018 被引用: 257

  20. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Petros Grivas - Clinical Cancer Research 2022 被引用: 48

  21. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 333

  22. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer

    著者: , , , , , , , , , , , , , , , , - Nature Communications 2022 被引用: 62

  23. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

    著者: , , , , , , , , , , , , , , , - European Urology Oncology 2023 被引用: 30

  24. Identification of 22 susceptibility loci associated with testicular germ cell tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ragnhild A. Lothe, Jennifer T. Loud, Chey Loveday, Paloma Martín, Coby Meijer, Jérémie Nsengimana, David I. Quinn, Þórunn Rafnar, Shweta Ramdas, Lorenzo Richiardi, Rolf I. Skotheim, Kāri Stefánsson, Clare Turnbull, David J. Vaughn, Fredrik Wiklund, Xifeng Wu, Daphne Yang, Tongzhang Zheng, Andrew D. Wells, Struan F.A. Grant, Ewa Rajpert‐De Meyts, Stephen M. Schwartz, D. Timothy Bishop, Katherine A. McGlynn, Peter A. Kanetsky, Katherine L. Nathanson, Christian Kubisch - Nature Communications 2021 被引用: 73